Alector (ALEC) Corporate presentation summary

Pipeline overview and strategic focus

• Advancing a proprietary Alector Brain Carrier (ABC) platform to enhance blood-brain barrier delivery for multiple CNS therapeutics, including antibodies, siRNA, and enzyme replacement therapies.

• Lead assets target Alzheimer's (AD), Parkinson's (PD), and Lewy Body Dementia (LBD), with first-in-human studies planned for 2027–2028.

• Platform enables subcutaneous (SC) delivery, high brain exposure, and aims to minimize adverse effects like ARIA, anemia, and infusion reactions.

• Multi-asset pipeline includes AL137 (anti-amyloid beta), AL064/AL164 (Tau siRNA), ADP062 (α-Syn siRNA), ADP065 (NLRP3 siRNA), and AL050 (GCase ERT).

• Strategic value is enhanced by full platform ownership and optionality for partnerships or independent growth.

AL137: Next-generation anti-amyloid beta antibody

• Engineered for high brain penetration, full effector function, and SC delivery, aiming for superior efficacy and safety over prior generations.

• Demonstrates 32x higher brain uptake in NHPs compared to competitors, with improved hematologic profile and minimal anemia or infusion reactions.

• Preclinical data show robust amyloid plaque binding, microglial engagement, and amyloid reduction in animal models.

• Phase 1 clinical plan includes SC dosing in healthy volunteers and early AD patients, targeting strong amyloid clearance with low ARIA and anemia rates.

• Well-tolerated in NHPs at high doses, supporting scalability and safety for clinical development.

AL064/AL164: Brain-penetrant Tau siRNA

• Designed for systemic (IV/SC) delivery to achieve broad, homogeneous brain distribution and intracellular Tau knockdown.

• Demonstrates potent, durable MAPT mRNA and pTau217 protein reduction in NHP brain and CSF after peripheral dosing.

• Achieves up to 130 nM brain siRNA levels and ~70% mRNA knockdown in NHPs, with strong in vitro potency across cell types.

• Aims to overcome limitations of intrathecal ASOs and antibody therapies for Tau pathology.

• First-in-human studies targeted for 2027/2028.